Semax: A Research Compound Overview

Semax is a synthetic heptapeptide derived from the N-terminal sequence of adrenocorticotropic hormone (ACTH 4-7) with a stabilizing Pro-Gly-Pro C-terminal extension. Originally developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in Moscow, Semax has been studied primarily in Russian research institutions since the 1980s and is registered in Russia and Ukraine for clinical use in ischemic stroke, transient ischemic attack, and cognitive impairment. Outside of these jurisdictions, it remains an active preclinical research compound with a growing Western research literature focused on neuroprotection, BDNF signaling, and cognitive modulation.

For researchers investigating neurotrophic factor regulation, neuroprotective mechanisms in ischemia models, or peptide-based cognitive modulation, Semax offers a well-characterized synthetic neuropeptide with a distinctive ACTH-derived pharmacology and a body of published research spanning over three decades.

What is Semax?

Semax is a heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP). The first four residues (Met-Glu-His-Phe) correspond to ACTH residues 4-7 — the fragment responsible for ACTH’s direct neurological effects in the CNS, distinct from its adrenal-stimulating activity which requires the full-length hormone. The C-terminal Pro-Gly-Pro extension was added during development to increase proteolytic stability and extend the peptide’s half-life in biological fluids compared to the native ACTH 4-7 fragment.

Unlike the full ACTH hormone, Semax does not stimulate cortisol secretion at research doses — a critical pharmacological distinction that separates its central neurological effects from the systemic endocrine activity of ACTH. This specificity has made Semax useful as a research tool for examining central melanocortin and neurotrophic pathways without the confounding influence of corticosteroid elevation that would accompany ACTH administration.

Semax is supplied as a white lyophilized powder and is water-soluble, reconstituting readily in bacteriostatic water or saline. Its small molecular size and water solubility make it compatible with intranasal delivery in addition to conventional parenteral administration — a route that has been used in Russian clinical research and that provides a practical research advantage for CNS-targeted study designs.

Molecular Profile

Semax Research: Key Areas of Study

BDNF Upregulation and Neurotrophic Signaling

The most extensively documented molecular effect of Semax in preclinical research is its ability to upregulate brain-derived neurotrophic factor (BDNF) and its receptor TrkB (tropomyosin receptor kinase B) in the central nervous system. BDNF is the most abundant neurotrophic factor in the brain and plays fundamental roles in neuronal survival, synaptic plasticity, long-term potentiation, and the maintenance of neuronal circuits underlying learning and memory.

Multiple studies in rodent models have documented increased BDNF mRNA expression and protein levels in hippocampal and cortical tissue following Semax administration. Research has demonstrated upregulation of both BDNF and TrkB in the hippocampus — the brain region central to spatial learning and memory consolidation — with treated groups showing elevated neurotrophic signaling that researchers have correlated with improved performance in hippocampus-dependent behavioral tasks.

The BDNF upregulation effect appears to occur through transcriptional mechanisms — research has examined Semax’s effects on BDNF promoter activity and on upstream regulators of BDNF expression including CREB (cAMP response element binding protein) phosphorylation. Studies have also investigated the temporal dynamics of BDNF elevation, characterizing the onset and duration of upregulation relative to Semax administration timing — information relevant to designing research protocols with optimal neurotrophin measurement timepoints.

Neuroprotection in Ischemia Models

Semax’s neuroprotective properties in ischemia and reperfusion injury models have been a primary driver of its clinical development and ongoing research interest. Russian clinical trials that supported its registration for ischemic stroke examined both the efficacy of Semax in reducing neurological deficit severity and in accelerating functional recovery following cerebrovascular events.

Preclinical research in rat models of focal cerebral ischemia has documented reduced infarct volume in Semax-treated groups compared to vehicle controls, alongside preservation of neurological performance scores. Mechanistic studies have examined multiple candidate neuroprotective pathways, including reduction of apoptotic signaling in the ischemic penumbra, attenuation of inflammatory cytokine production in microglial cells, and preservation of mitochondrial function in neurons subjected to hypoxic challenge.

Research has also examined the timing sensitivity of Semax’s neuroprotective effects in ischemia models — an important practical consideration for both clinical and preclinical research design. Studies suggest a time-dependent protection window consistent with intervention in the early post-ischemic phase, with effects diminishing when administration is delayed beyond the acute injury period.

Cognitive Performance Research

Beyond acute neuroprotection, research has examined Semax’s effects on baseline cognitive performance in both intact animals and models of cognitive impairment. Studies using spatial memory paradigms — including the Morris water maze and radial arm maze — have reported significant improvements in learning rate and memory retention in Semax-treated rodents compared to vehicle controls.

Research in aging rodent models has examined whether Semax administration can attenuate age-related cognitive decline, with some studies reporting preserved performance on memory tasks in aged, Semax-treated animals compared to age-matched controls. The BDNF upregulation mechanism is considered a plausible mediator of these cognitive effects — BDNF is essential for long-term potentiation, the synaptic strengthening mechanism underlying memory consolidation, and its decline with aging is associated with reduced synaptic plasticity and cognitive performance.

Human research conducted in Russia has examined Semax in patients with cognitive impairment associated with cerebrovascular disease, reporting improvements in attention, memory, and psychomotor speed parameters. These clinical studies, while limited in sample size and methodological rigor by Western standards, provide translational context for interpreting the preclinical cognitive research literature.

Dopaminergic and Serotonergic System Research

Research has examined Semax’s effects on dopaminergic and serotonergic neurotransmission — monoamine systems that regulate mood, motivation, attention, and executive function. Studies measuring extracellular dopamine and serotonin levels in brain regions using microdialysis have reported Semax-associated increases in dopamine turnover in prefrontal cortical regions, consistent with the cognitive-enhancing profile observed in behavioral studies.

The relationship between ACTH 4-7 and dopaminergic function has been studied since the 1970s, when early research documented that ACTH fragments modulate motivational behavior and dopamine-dependent reward learning in animal models. Semax’s pharmacological profile builds on this ACTH fragment biology, and research has examined whether its dopaminergic effects represent a direct action on dopamine synthesis or release, or an indirect effect mediated by BDNF-driven neuronal plasticity.

Anti-Inflammatory and Antioxidant Mechanisms

Neuroinflammation and oxidative stress are central pathological mechanisms in acute brain injury and neurodegenerative disease, and research has examined whether Semax’s neuroprotective effects involve modulation of these processes. Studies in ischemia models have reported reduced microglial activation markers and lower pro-inflammatory cytokine levels (TNF-α, IL-1β, IL-6) in Semax-treated brain tissue compared to controls.

Antioxidant research has documented Semax-associated reductions in markers of oxidative stress including lipid peroxidation products and protein carbonylation in treated brain tissue. Some studies have reported upregulation of antioxidant enzyme expression, particularly superoxide dismutase, in regions of the brain most vulnerable to oxidative damage during ischemic events. These anti-inflammatory and antioxidant properties are considered integral components of Semax’s neuroprotective mechanism rather than independent effects.

Semax and BDNF-TrkB Signaling: The Central Mechanism

BDNF signaling through its high-affinity receptor TrkB represents the primary molecular mechanism through which researchers have sought to explain Semax’s cognitive and neuroprotective effects. When BDNF binds TrkB, receptor dimerization activates intracellular tyrosine kinase domains that initiate signaling cascades through three principal pathways: the RAS-MAPK pathway (regulating gene transcription and neuronal differentiation), the PI3K-Akt pathway (regulating neuronal survival and protein synthesis), and the PLCγ-PKC pathway (regulating synaptic plasticity and calcium-dependent signaling).

Each of these downstream pathways has been examined in the context of Semax research. MAPK activation in hippocampal neurons is associated with the induction of plasticity-related gene expression including Arc and c-Fos — immediate-early genes required for long-term memory formation. PI3K-Akt activation provides anti-apoptotic signaling through phosphorylation of pro-apoptotic proteins, contributing to neuronal survival in stress conditions. PLCγ activation promotes calcium release that enables long-term potentiation at glutamatergic synapses.

The precise molecular mechanisms through which Semax — a small heptapeptide — initiates BDNF upregulation remain an active area of research. Current evidence points to effects on CREB phosphorylation and transcriptional regulation of BDNF promoters, potentially mediated through melanocortin receptor-linked signaling pathways that the ACTH-derived sequence may activate. Researchers continue to characterize these upstream mechanisms to determine whether Semax acts as a direct transcriptional regulator of BDNF expression or through receptor-mediated second messenger cascades.

Stability and Research Considerations

Semax’s Pro-Gly-Pro extension was specifically designed to increase resistance to peptidase degradation compared to the native ACTH 4-7 sequence. While this modification improves stability relative to its parent sequence, standard peptide handling precautions remain important for maintaining compound activity in research applications.

Intranasal versus parenteral delivery: Published Semax research includes both intranasal and parenteral (subcutaneous or intraperitoneal) administration routes in animal models. Intranasal delivery may provide direct transport to CNS tissue via the olfactory epithelium pathway. Researchers should specify delivery route when comparing results to published literature, as the pharmacokinetic profiles differ substantially between routes.

Methionine oxidation: Semax contains a methionine residue (position 1) that is susceptible to oxidation in solution, particularly in the presence of trace metal contaminants or light exposure. Oxidized methionine reduces biological activity. Prepare working solutions in metal-free buffer and minimize light exposure during experimental procedures.

Behavioral assay timing: Research examining Semax’s cognitive effects using behavioral paradigms should account for the delayed onset of BDNF-driven neuroplastic changes. Acute cognitive effects may reflect monoaminergic mechanisms, while longer-duration studies are required to capture BDNF-mediated structural plasticity changes. Experimental designs should include appropriate timepoints for both acute and sustained effect characterization.

Strain differences in rodent research: Semax research has predominantly used Wistar and Sprague-Dawley rat strains. Researchers using other strains, or mouse models, should anticipate potential differences in baseline BDNF expression, melanocortin receptor pharmacology, and behavioral performance that may affect reproducibility of published results.

Sourcing Semax for Research

Official Peptides supplies research-grade Semax at >99% purity verified by HPLC and confirmed by mass spectrometry. Each batch is tested by an independent third-party laboratory, with batch-specific certificates of analysis available for every purchase. Our Semax is manufactured from high-purity amino acid building blocks under controlled synthesis conditions and ships from a US-based facility with cold pack packaging.

For researchers studying the neuropeptide pharmacology of ACTH-derived sequences, Official Peptides maintains complementary inventory including Selank and other synthetic neuropeptides of research interest.

Order Semax from Official Peptides →